MedPath

Measurement of WT1-mRNA in Acute Myeloid Leukemia Patients

Not Applicable
Completed
Conditions
Acute Myeloid Leukemia
Registration Number
JPRN-jRCT1090220061
Lead Sponsor
Shuichi Miyawaki;Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria

Untreated, de novo AML patients, who are positi
ve for WT1-mRNA at diagnosis and without previous history of myelodysplastic syndrome.

Exclusion Criteria

AML cases who did not achieve complete remission after one-/two- course of remission-induction therapy.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Correlation between the comparison of WT1-mRNA of pre- with post-chemotherapy and 2-year relapse-free survival.
Secondary Outcome Measures
NameTimeMethod
Correlation between characteristics of the patients and the change of WT1-mRNA level and survival.
© Copyright 2025. All Rights Reserved by MedPath